Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
3.100
-0.170 (-5.20%)
Streaming Delayed Price
Updated: 3:48 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme
January 17, 2024
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
January 04, 2024
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
December 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Preview: Lisata Therapeutics
November 01, 2023
Via
Benzinga
Lisata Therapeutics to Present at NobleCon19 Investor Conference
November 28, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in November
November 09, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time
October 26, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
October 24, 2023
Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors...
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
October 17, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
September 28, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in InfoSec World 2023
September 20, 2023
Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligence
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
September 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
September 06, 2023
Independent Data Safety Monitoring Committee recommends study continuation (criteria for futility not met)
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
September 05, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
August 08, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
August 07, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
July 11, 2023
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
June 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
May 24, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time
May 02, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in May
April 27, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
April 20, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
April 18, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
Conference call scheduled for today at 4:30 p.m. Eastern time
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 30, 2023
March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via
Benzinga
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
March 23, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.